A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

NCT06952530 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

487

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: Orforglipron
DRUG: Placebo

Sponsor

Eli Lilly and Company